{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:30:32Z","timestamp":1740133832005,"version":"3.37.3"},"reference-count":19,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"DOI":"10.1136\/bjo-2024-325182","type":"journal-article","created":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T18:25:22Z","timestamp":1707243922000},"page":"bjo-2024-325182","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Pan-Indian multicentre retrospective study of 0.01% atropine for myopia control"],"prefix":"10.1136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2156-1486","authenticated-orcid":false,"given":"Jason C","family":"Yam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8515-3388","authenticated-orcid":false,"given":"Yuzhou","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,2,6]]},"reference":[{"key":"2024020610251002000_bjo-2024-325182v1.1","doi-asserted-by":"crossref","unstructured":"Saxena R , Gupta V , Dhiman R , et al . Low-dose atropine 0.01% for the treatment of childhood myopia: a pan-India multicentric retrospective study. Br J Ophthalmol 2024:bjo-2023-324450. doi:10.1136\/bjo-2023-324450","DOI":"10.1136\/bjo-2023-324450"},{"key":"2024020610251002000_bjo-2024-325182v1.2","doi-asserted-by":"crossref","unstructured":"Haarman AEG , Enthoven CA , Tideman JWL , et al . The complications of myopia: A review and meta-analysis. Invest Ophthalmol Vis Sci 2020;61:49. doi:10.1167\/iovs.61.4.49","DOI":"10.1167\/iovs.61.4.49"},{"key":"2024020610251002000_bjo-2024-325182v1.3","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.ophtha.2021.01.026","article-title":"Atropine for the treatment of childhood myopia in India: Multicentric randomized trial","volume":"128","author":"Saxena","year":"2021","journal-title":"Ophthalmology"},{"key":"2024020610251002000_bjo-2024-325182v1.4","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1111\/1471-0528.15199","article-title":"Randomised controlled trials - the gold standard for effectiveness research: study design: randomised controlled trials","volume":"125","author":"Hariton","year":"2018","journal-title":"BJOG"},{"key":"2024020610251002000_bjo-2024-325182v1.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.05.029"},{"key":"2024020610251002000_bjo-2024-325182v1.6","doi-asserted-by":"crossref","unstructured":"Morgan IG , Wu P-C , Ostrin LA , et al . IMI risk factors for myopia. Invest Ophthalmol Vis Sci 2021;62:3. doi:10.1167\/iovs.62.5.3","DOI":"10.1167\/iovs.62.5.3"},{"key":"2024020610251002000_bjo-2024-325182v1.7","doi-asserted-by":"crossref","unstructured":"Zhang XJ , Zhang Y , Kam KW , et al . Prevalence of myopia in children before, during, and after COVID-19 restrictions in Hong Kong. JAMA Netw Open 2023;6:e234080. doi:10.1001\/jamanetworkopen.2023.4080","DOI":"10.1001\/jamanetworkopen.2023.4080"},{"key":"2024020610251002000_bjo-2024-325182v1.8","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2021-319307"},{"key":"2024020610251002000_bjo-2024-325182v1.9","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1111\/ceo.14148","article-title":"Low-concentration atropine Eyedrops for myopia control in a multi-racial cohort of Australian children: A randomised clinical trial","volume":"50","author":"Lee","year":"2022","journal-title":"Clin Exp Ophthalmol"},{"key":"2024020610251002000_bjo-2024-325182v1.10","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/jamaophthalmol.2023.2855","article-title":"Low-dose 0.01% atropine eye drops vs placebo for myopia control: A randomized clinical trial","volume":"141","author":"Repka","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"2024020610251002000_bjo-2024-325182v1.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.12.011"},{"key":"2024020610251002000_bjo-2024-325182v1.12","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ophtha.2021.10.002","article-title":"Three-year clinical trial of low-concentration atropine for myopia progression (LAMP) study: continued versus Washout","volume":"129","author":"Yam","year":"2022","journal-title":"Ophthalmology"},{"key":"2024020610251002000_bjo-2024-325182v1.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.12.036"},{"key":"2024020610251002000_bjo-2024-325182v1.14","doi-asserted-by":"crossref","unstructured":"P\u00e9rez-Flores I , Mac\u00edas-Murelaga B , Barrio-Barrio J , et al . Age-related results over 2 years of the multicenter Spanish study of atropine 0.01% in childhood myopia progression. Sci Rep 2023;13:16310. doi:10.1038\/s41598-023-43569-x","DOI":"10.1038\/s41598-023-43569-x"},{"key":"2024020610251002000_bjo-2024-325182v1.15","doi-asserted-by":"crossref","unstructured":"Myles W , Dunlop C , McFadden SA . The effect of long-term low-dose atropine on refractive progression in myopic Australian school children. J Clin Med 2021;10:1444. doi:10.3390\/jcm10071444","DOI":"10.3390\/jcm10071444"},{"key":"2024020610251002000_bjo-2024-325182v1.16","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1089\/jop.2011.0027","article-title":"The long-term results of using low-concentration atropine eye drops for controlling myopia progression in schoolchildren","volume":"27","author":"Wu","year":"2011","journal-title":"J Ocul Pharmacol Ther"},{"key":"2024020610251002000_bjo-2024-325182v1.17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41433-018-0139-7","article-title":"Update in myopia and treatment strategy of atropine use in myopia control","volume":"33","author":"Wu","year":"2019","journal-title":"Eye (Lond)"},{"key":"2024020610251002000_bjo-2024-325182v1.18","doi-asserted-by":"crossref","unstructured":"Li Y , Yip M , Ning Y , et al . Topical atropine for childhood myopia control: the atropine treatment long-term assessment study. JAMA Ophthalmol 2023:e235467. doi:10.1001\/jamaophthalmol.2023.5467","DOI":"10.1001\/jamaophthalmol.2023.5467"},{"key":"2024020610251002000_bjo-2024-325182v1.19","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1001\/jama.2022.24162","article-title":"Effect of low-concentration atropine Eyedrops vs placebo on myopia incidence in children: the Lamp2 randomized clinical trial","volume":"329","author":"Yam","year":"2023","journal-title":"JAMA"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjo-2024-325182","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T18:25:29Z","timestamp":1707243929000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjo-2024-325182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,6]]},"references-count":19,"alternative-id":["10.1136\/bjo-2024-325182"],"URL":"https:\/\/doi.org\/10.1136\/bjo-2024-325182","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"type":"print","value":"0007-1161"},{"type":"electronic","value":"1468-2079"}],"subject":[],"published":{"date-parts":[[2024,2,6]]}}}